3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2/3
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
8
Gastrointestinal
6
Gynecologic
5
Thoracic
3
Genitourinary
2
CNS
2
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
93
Doxorubicin
92
Radiotherapy
87
Temozolomide
69
Filgrastim
58
Ifosfamide
55
Bevacizumab
55
Etoposide
48
Gemcitabine
44
Imatinib Mesylate
43
Vincristine
40
pembrolizumab
35
pazopanib
34
Peripheral Blood Stem Cell Transplantation
31
Methotrexate
31
Nivolumab
30
Carboplatin
30
fludarabine phosphate
29
Irinotecan
29
Cisplatin
28
Paclitaxel
26
Melphalan
26
Magnetic Resonance Spectroscopy
26
Docetaxel
25
Busulfan
25
Trabectedin
24
apatinib
22
Specimen Handling
21
Sirolimus
21
Antilymphocyte Serum
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
veliparib
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled